NutriDex

The Supplement Research Compendium
🌿

Fructooligosaccharides (FOS)

Oligofructose

A bifidogenic prebiotic fiber with solid microbiome and constipation data — metabolic benefits mostly in diabetes.

Moderate evidence 🌾Prebiotics & Fibers🛡️Gut & Immune

✚ Updated · How we grade evidence

Evidence tier
Moderate
Research weight
Citations
10 verified / 10
Classification
Prebiotics & Fibers
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.

What is Fructooligosaccharides (FOS)?

Fructooligosaccharides (FOS) (Oligofructose) is a prebiotic fiber used for bifidogenic microbiome shift: meta-analysis of 8 rcts found fos significantly raises colonic bifidobacterium (smd 0.58, 95% ci 0.44-0.71), with larger effects at >5 g/day and >4 weeks; lactobacillus is not significantly changed.. NutriDex grades the human evidence as Moderate. Fructooligosaccharides (FOS, also called oligofructose) are short-chain inulin-type fructans (typically 2-10 fructose units) extracted from chicory root or synthesized from sucrose, fermented in the colon to short-chain fatty acids. The strongest human evidence is for a reproducible bifidogenic shift in the gut microbiome and modest relief of functional constipation. Effects on fasting glucose and blood lipids are real but concentrated in people with diabetes/prediabetes and are minimal in metabolically healthy adults; weight and appetite effects are small. As a highly fermentable FODMAP, FOS reliably causes dose-dependent gas and bloating, and it can transiently worsen symptoms in IBS.

Purported Benefits

✓Bifidogenic microbiome shift: meta-analysis of 8 RCTs found FOS significantly raises colonic Bifidobacterium (SMD 0.58, 95% CI 0.44-0.71), with larger effects at >5 g/day and >4 weeks; Lactobacillus is not significantly changed.
✓Functional constipation: meta-analysis of 17 RCTs (713 people) found increased stool frequency, softer stool consistency (SMD 0.36, 95% CI 0.12-0.60), and less straining/pain during defecation (SMD -0.60, 95% CI -0.85 to -0.34).
✓Glycemic control mainly in diabetes: inulin-type fructan RCTs show lower fasting glucose (WMD -0.42 mmol/L, 95% CI -0.71 to -0.14), but the benefit was seen in diabetic/prediabetic subgroups, not in healthy adults.
✓Lipids in diabetes: same fructan meta-analysis showed reduced total cholesterol (-0.46 mmol/L), LDL (-0.30 mmol/L) and triglycerides (-0.21 mmol/L), again chiefly in diabetic subgroups — note FOS itself carries no FDA heart-health claim (that applies to oat beta-glucan and psyllium).
✓Modest appetite/weight effect: 21 g/day oligofructose for 12 weeks produced ~1.0 kg weight loss vs +0.45 kg on placebo, with lower ghrelin and higher PYY (satiety hormones).
✓Calcium absorption/bone: short+long-chain inulin-type fructan blends (containing oligofructose) increased calcium absorption and bone mineralization in adolescents — robust for mixed fructans, less established for pure FOS.

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Bifidogenic microbiome shift (↑Bifidobacterium)Meta-analysis of 8 RCTs (SMD 0.58) with larger effects >5 g/day; Lactobacillus unchanged. Strong ↑ benefit · moderate 2
Functional constipation relief (stool frequency, consistency, less straining)Meta-analysis of 17 RCTs (713 people) shows softer stools and less straining; mild bloating the main adverse event. Strong ↑ benefit · moderate 2
Fasting glucose lowering (diabetic/prediabetic subgroups)Fructan meta-analysis shows lower fasting glucose, but benefit confined to diabetics; a 2025 prediabetes RCT found no glucose effect. Moderate ↔ mixed · small 2
Blood lipid lowering (total/LDL cholesterol, triglycerides) in diabetesSame fructan meta-analysis; reductions chiefly in diabetic subgroups, not healthy adults. Moderate ↑ benefit · small 1
Modest weight loss / appetite reductionSingle RCT: 21 g/day oligofructose gave ~1 kg loss with lower ghrelin/higher PYY. Preliminary ↑ benefit · small 1
Calcium absorption / bone mineralizationShown for mixed short+long-chain fructan blends in adolescents; less established for pure FOS. Preliminary ↑ benefit · moderate 1

Dosing & Compounds

Typical Dose
Typical effective dose is about 5-15 g/day (trials range ~2.5-21 g/day), taken as a powder mixed into food or drink, or in divided doses with meals. Bifidogenic and constipation effects are seen from ~5 g/day; start low (2-5 g/day) and titrate up over 1-2 weeks to limit gas. Higher metabolic doses (e.g. ~21 g/day used in weight/appetite trials) markedly increase GI side effects.
Active Compounds
Supplements: chicory-derived oligofructose powders (Beneo Orafti P95/Synergy1), NOW Oligofructose, Jarrow/other 'FOS' or 'inulin-FOS' powders and capsulesSynthetic short-chain FOS (scFOS) from sucrose (e.g. Nutraflora/GTC)Food sources: chicory root, Jerusalem artichoke, onion, garlic, leek, asparagus, banana, wheat and ryeCommonly added as a 'prebiotic fiber' to yogurts, infant formula, bars and fiber-fortified foods

Safety & Cautions

FOS is a fermentable FODMAP, so the main issue is dose-dependent flatulence, bloating, abdominal discomfort and loose stools; tolerance is usually good up to ~5-10 g/day and side effects rise sharply above ~15-20 g/day. People with IBS or SIBO can have symptoms transiently worsen and may need to avoid it (it is restricted on the low-FODMAP diet). Like other viscous/fermentable fibers, take it separated from medications by a couple of hours, as fiber can delay or reduce drug absorption. Begin low and increase gradually, and ensure adequate fluid intake. It is not associated with the choking/esophageal-obstruction hazard of bulk-forming gel fibers like glucomannan/konjac, but powders should still be taken with liquid. Educational only — always check with your doctor or pharmacist before combining Fructooligosaccharides (FOS) with any medicine.

Key Studies ★ 10 studies

Systematic review / meta-analysis Zhen 2024 (Nutrients, syst review & meta-analysis) ✓ Full text
Across 17 RCTs (713 participants), FOS increased stool frequency, softened stool consistency (SMD 0.36, 95% CI 0.12-0.60) and reduced straining/pain (SMD -0.60, 95% CI -0.85 to -0.34) in functional constipation, with mild bloating as the main adverse event.
Meta-analysis Nutrients 2025 ✓ Full text
Systematic review and meta-analysis of 20 RCTs (n=1,786) of non-digestible oligosaccharides found supplementation significantly increased stool frequency, with a larger effect in constipated individuals (SMD 0.99, 95% CI 0.58-1.28).
Systematic review / meta-analysis Cheng 2022 (Front Nutr, meta-analysis) ✓ Full text
Pooling 8 RCTs (213 FOS vs 175 controls), FOS significantly increased colonic Bifidobacterium (SMD 0.58, 95% CI 0.44-0.71), with greater effects at >5 g/day (0.86 vs 0.52) and >4 weeks, while Lactobacillus was unchanged.
Systematic review / meta-analysis Li 2021 (Clin Nutr ESPEN, meta-analysis of RCTs) ✓ Full text
Across 33 RCTs of inulin-type fructans, fasting glucose fell (WMD -0.42 mmol/L, 95% CI -0.71 to -0.14) along with total cholesterol, LDL and triglycerides, but significant benefit was confined to diabetic/prediabetic subgroups, not healthy subjects.
Meta-analysis Bifidobacterium meta-analysis 2022 ✓ Full text
Systematic review and meta-analysis of 8 studies (213 FOS recipients vs 175 controls) found FOS supplementation significantly increased Bifidobacterium counts compared with controls, confirming a bifidogenic effect in humans.
RCT scFOS prediabetes RCT 2025 ✓ Full text
In a 12-week double-blind placebo-controlled RCT (n=66) in overweight prediabetic adults, 20 g/day short-chain FOS significantly increased Bifidobacterium and fecal acetate/propionate with modest body composition improvement, but showed no significant effect on HbA1c or glucose metabolism.
Randomized controlled trial Liu 2017 (Sci Rep, RCT, scFOS) ✓ Full text
Short-chain FOS increased Bifidobacterium and other beneficial taxa but also reduced butyrate-producing bacteria, and high-dose short-term intake was associated with adverse oral-glucose-tolerance responses in healthy young adults.
Randomized controlled trial Tandon 2019 (Sci Rep, dose-response RCT) ✓ Source
A dose-response, double-blind, placebo-controlled trial in healthy adults confirmed FOS dose-dependently shifts gut microflora (notably Bifidobacterium) while characterizing GI tolerance across doses.
Randomized controlled trial Parnell 2009 (Am J Clin Nutr, RCT) ✓ PubMed
In 48 overweight/obese adults, 21 g/day oligofructose for 12 weeks produced -1.03 kg weight change vs +0.45 kg on placebo (P=0.01), with ~23% lower ghrelin AUC and ~13% higher PYY AUC.
Randomized controlled trial Abrams 2005 (Am J Clin Nutr, RCT) ✓ PubMed
In adolescents, 8 g/day of a short- plus long-chain inulin-type fructan (oligofructose+inulin) increased calcium absorption at 8 weeks (+8.5%) and 1 year (+5.9%) and enhanced bone mineral density vs maltodextrin placebo.
10 sources cited · 10 verified Search all studies on PubMed ↗

Common questions about Fructooligosaccharides (FOS)

What is Fructooligosaccharides (FOS) used for?

Fructooligosaccharides (FOS) is most often taken for Bifidogenic microbiome shift: meta-analysis of 8 RCTs found FOS significantly raises colonic Bifidobacterium (SMD 0.58, 95% CI 0.44-0.71), with larger effects at >5 g/day and >4 weeks; Lactobacillus is not significantly changed., Functional constipation: meta-analysis of 17 RCTs (713 people) found increased stool frequency, softer stool consistency (SMD 0.36, 95% CI 0.12-0.60), and less straining/pain during defecation (SMD -0.60, 95% CI -0.85 to -0.34)., Glycemic control mainly in diabetes: inulin-type fructan RCTs show lower fasting glucose (WMD -0.42 mmol/L, 95% CI -0.71 to -0.14), but the benefit was seen in diabetic/prediabetic subgroups, not in healthy adults., Lipids in diabetes: same fructan meta-analysis showed reduced total cholesterol (-0.46 mmol/L), LDL (-0.30 mmol/L) and triglycerides (-0.21 mmol/L), again chiefly in diabetic subgroups — note FOS itself carries no FDA heart-health claim (that applies to oat beta-glucan and psyllium).. A bifidogenic prebiotic fiber with solid microbiome and constipation data — metabolic benefits mostly in diabetes.

Does Fructooligosaccharides (FOS) work — what does the evidence say?

Moderate evidence. Several controlled trials; effects real but modest or context-dependent. Fructooligosaccharides (FOS, also called oligofructose) are short-chain inulin-type fructans (typically 2-10 fructose units) extracted from chicory root or synthesized from sucrose, fermented in the colon to short-chain fatty acids. The strongest human evidence is for a reproducible bifidogenic shift in the gut microbiome and modest relief of functional constipation. Effects on fasting glucose and blood lipids are real but concentrated in people with diabetes/prediabetes and are minimal in metabolically healthy adults; weight and appetite effects are small. As a highly fermentable FODMAP, FOS reliably causes dose-dependent gas and bloating, and it can transiently worsen symptoms in IBS.

What is the typical dose of Fructooligosaccharides (FOS)?

Typical effective dose is about 5-15 g/day (trials range ~2.5-21 g/day), taken as a powder mixed into food or drink, or in divided doses with meals. Bifidogenic and constipation effects are seen from ~5 g/day; start low (2-5 g/day) and titrate up over 1-2 weeks to limit gas. Higher metabolic doses (e.g. ~21 g/day used in weight/appetite trials) markedly increase GI side effects.

Is Fructooligosaccharides (FOS) safe? Any cautions or side effects?

FOS is a fermentable FODMAP, so the main issue is dose-dependent flatulence, bloating, abdominal discomfort and loose stools; tolerance is usually good up to ~5-10 g/day and side effects rise sharply above ~15-20 g/day. People with IBS or SIBO can have symptoms transiently worsen and may need to avoid it (it is restricted on the low-FODMAP diet). Like other viscous/fermentable fibers, take it separated from medications by a couple of hours, as fiber can delay or reduce drug absorption. Begin low and increase gradually, and ensure adequate fluid intake. It is not associated with the choking/esophageal-obstruction hazard of bulk-forming gel fibers like glucomannan/konjac, but powders should still be taken with liquid.

How many studies support Fructooligosaccharides (FOS)?

NutriDex cites 10 sources for Fructooligosaccharides (FOS), graded "Moderate".

Cite this page
APA

Peh, D. (2026). Fructooligosaccharides (FOS) (Oligofructose): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/fos

BibTeX
@misc{nutridex_fos,
  author       = {Peh, Daryl},
  title        = {Fructooligosaccharides (FOS) (Oligofructose): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/fos},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances